Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.19 -0.16 (-0.66%)

Streaming Delayed Price Updated: 10:56 AM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Why the growth investor may take a look at NASDAQ:CPRX. ↗

August 21, 2023

CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+ ↗

August 16, 2023

Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Via Investor's Business Daily

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

August 16, 2023

Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗

August 15, 2023

One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81.

Via Investor's Business Daily

5 Analysts Have This to Say About Catalyst Pharmaceuticals ↗

August 11, 2023

Via Benzinga

Where Catalyst Pharmaceuticals Stands With Analysts ↗

July 21, 2023

Via Benzinga

The Latest Analyst Ratings for Catalyst Pharmaceuticals ↗

June 21, 2023

Via Benzinga

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

August 15, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

Exelixis Stock Sees Rising Relative Strength Rating ↗

August 14, 2023

On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.

Via Investor's Business Daily

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

August 14, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

August 09, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals: Q1 Earnings Insights ↗

May 10, 2023

Via Benzinga

7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now ↗

August 03, 2023

Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts.

Via InvestorPlace

Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

July 25, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

July 24, 2023

The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

July 19, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing ↗

July 02, 2023

Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential.

Via InvestorPlace

ETF Returns: Mid-Cap Winners And Losers ↗

June 28, 2023

We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...

Via Benzinga

Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know ↗

June 21, 2023

Via Benzinga

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

June 20, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

The 7 Best Stocks Under $15 to Buy in June 2023 ↗

June 01, 2023

While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.

Via InvestorPlace

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

June 01, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

May 30, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy? ↗

May 22, 2023

When evaluating investments, it helps to keep quarterly performance in context.

Via The Motley Fool

Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

May 15, 2023

Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.

Via Investor's Business Daily

Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review ↗

May 12, 2023

The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones.

Via Investor's Business Daily

IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth ↗

May 11, 2023

Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.

Via Investor's Business Daily

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

May 10, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 11, 2023

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.

Via Benzinga

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

May 09, 2023

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.